RANTPRO-75 is positioned as an H2-receptor antagonist for acid-related gastrointestinal care, intended to reduce gastric acid secretion and provide symptomatic support in appropriate acid-mediated conditions. Because ranitidine products have undergone major regulatory changes related to NDMA concerns, the exact formulation and market authorization should be verified before this product is included in a PCD Pharma commercial catalogue. FDA approved a reformulated ranitidine product in November 2025 following a safety review. (U.S. Food and Drug Administration)
Acid-related gastrointestinal conditions.
Regulatory status varies by market and formulation.
Verify the exact approved formulation, current local regulatory status and applicable prescribing information before promotion or distribution.
Headache, nausea, abdominal discomfort, diarrhea or constipation may occur.
RANTPRO-75: Ranitidine is an H2-receptor antagonist that reduces gastric acid secretion by blocking histamine H2 receptors on gastric parietal cells.
